1Fleischmajer R, Kuroda K, Hazan R, et al.Basement membrane alterations in psoriasis are accompanied by epidermal overexpression of MMP-2 and its inhibitor TIMP-2. J Invest Dermatol, 2000, 115: 771-777.
2Suomela S, Kariniemi AL, Snellman E, et al. Metalloelastase (MMP-12) and 92-kDa gelatinase (MMP-9) as well as their inhibitors, TIMP-1 and -3, are expressed in psoriatic lesions. Exp Dermatol, 2001, 10:175-183.
3Fredriksson T, Pettersson U. Severe psoriasis-oral therapy with a new retinoid. Dermatologica, 1978, 157: 238-244.
2Garcia RL,Coltrera MD,Gown AM.Analysis of proliferative grade using anti PCNA/cyclin monoclonal antibodies in fixed, embedded tissues:comparison with flow cytometric analysis[].American Journal of Pathology.1988
3Krane JF,Murphy DP,Gottieb AB,et al.Increased dermal expression of platelet- derived growth factor receptors in growth- activated skin wounds and psoriasis[].Journal of Investigative Dermatology.1991
5Suomela S, Kariniemi AL, Snellman E, et al. Metalloelastase (MMP-12) and 92-kDa gelatinase (MMP-9) as well as their inhibitors, TIMP-1 and -3, are expressed in psoriatic lesions[J]. Exp Dermatol, 2001, 10(3): 175-183.
6Ruzicka T. Psoriatic arthritis. New types, new treatments[J]. Arch Dermatol, 1996, 132(2): 215-219.
7Weinstein GD, Frost P. Methotrexate for psoriasis. A new therapeutic schedule[J]. Arch Dermatol, 1971, 103(1): 33-38.
